Food Safety & Nutrition

Documents

EPAOpen for comment

Pesticide Tolerance; Exemptions, Petitions, Revocations, etc.: Petitions Filed for Residues of Pesticide Chemicals in or on Various Commodities—March 2026

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →Closes Jul 23
EPA

CH Biotech R&D Co., Ltd. Notice of Filing Pesticide Petition requesting, pursuant to section 408(d) of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a(d), to amend 40 CFR part 180 to establish an exemption from the requirement of a tolerance for the biochemical pesticide melatonin

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Letter from Tricia Spencer to FDA HFP

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDAOpen for comment

Citizen Petition from Windels Marx Lane & Mittendorf, LLP

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Acknowledgement Letter from FDA DMB to Windels Marx Lane & Mittendorf, LLP

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 1 - Draft Guidance on Dabrafenib Mesylate

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 2 - Criteria for waiver of evidence of in vivo bioavailability or bioequivalence

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 3 - Prescribing Information for TAFINLAR

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 4 - Petition to request a change from a listed drug

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 5 - Dabrafenib hard capsule 50 and 75 mg product-specific bioequivalence guidance

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 6 - Influence of Drug Properties and Formulation on In Vitro Drug Release and Biowaiver Regulation of Oral Extended Release Dosage Forms

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 7 - Improving the Dissolution Rate of the Anticancer Drug Dabrafenib

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →